Hematology-Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, Damas Street, PO Box 17-5208, 1104 2020, Lebanon.
Immunotherapy. 2022 Feb;14(2):155-167. doi: 10.2217/imt-2021-0014. Epub 2021 Dec 6.
Lung cancer is the second most common cancer worldwide and the leading cause of death among cancers. The progressive approvals of immunotherapy as first-line treatment options have helped improve cancer prognosis. However, longer follow-up has confirmed the possibility of acquired resistance to immune checkpoint inhibitors (ICIs) which can lead to late relapses. Chemotherapy can act as a priming therapy to increase a tumor's response to immunotherapy. We aim through this review to explain the mechanism behind ICI resistance and the value of chemotherapy in escaping this resistance. Finally, all US FDA approvals regarding the management of metastatic non-small-cell lung cancer using a combination of ICIs and chemotherapy are summarized.
肺癌是全球第二大常见癌症，也是癌症死亡的主要原因。免疫疗法作为一线治疗选择的逐步批准有助于改善癌症预后。然而，更长时间的随访证实了免疫检查点抑制剂（ICI）获得性耐药的可能性，这可能导致晚期复发。化疗可以作为一种启动治疗，增加肿瘤对免疫治疗的反应。我们旨在通过本综述解释 ICI 耐药背后的机制以及化疗在逃避这种耐药方面的价值。最后，总结了所有美国食品和药物管理局（FDA）关于使用 ICI 和化疗联合治疗转移性非小细胞肺癌的管理的批准。
